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Abstract: Hepatitis B virus (HBV) is an enveloped partial double-stranded DNA virus that can cause
acute and chronic hepatitis. According to the World Health Organization (WHO) and the Centers for
Disease Control and Prevention (CDC), 257 million people are living with HBV. Moreover, 20,900
acute hepatitis B cases were reported in 2016. Hepatitis B is highly prevalent in the African, Western
Pacific, Eastern Mediterranean, South-East Asia, and European regions, respectively. Due to the
high mutational rate of HBV and lack of reverse transcriptase proofreading activity, ten different
genotypes with different geographical distributions have been identified. HBV pathogenesis and
severity of infection depend on several host and viral factors, particularly, the genetic variability
of both the host and virus. Although HBV infection is a global health concern, there is a lack of
adequate studies and reports in the Middle East and North Africa (MENA) region. Here, we provide
a review on HBV epidemiology, pathogenesis, host–pathogen interactions, coinfection with selected
viruses, and laboratory diagnosis, focusing on studies conducted in the MENA region to determine
the current situation of the HBV infection and outline the future study areas.
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1. Introduction
Hepatitis is a worldwide health problem resulting in liver malfunction [1]. Although the primary
cause of hepatitis is viral infections including HBV, other non-viral causes such as toxins, drugs,
autoimmune diseases, infections with bacteria, as well as parasites, can also lead to hepatitis [2].
HBV is a partially double-stranded DNA virus that belongs to the Hepadnaviridae family, in the
Orthohepadnavirus genus [3]. It is the causative agent of hepatitis B infection, resulting in both acute
and chronic hepatitis infections. Chronic HBV infection can progress to hepatocellular carcinoma
(HCC) and liver cirrhosis and subsequently leads to death. Therefore, it is considered a life-threatening
virus worldwide, leading to significant rates of mortality [4]. According to WHO, 257 million people
are living with HBV infection with an estimated number of 887,000 deaths in 2015 attributed to
HBV complications [4]. In the USA, there are more than two million people living with chronic
HBV-infection [2]. According to WHO epidemiological map, HBV is classified as a highly endemic
Pathogens 2019, 8, 63; doi:10.3390/pathogens8020063 www.mdpi.com/journal/pathogens
Pathogens 2019, 8, 63 2 of 22
virus in the Western Pacific, sub-Saharan Africa, and in East Asia. In the Arabian Gulf region,
many immigrant workers come from highly HBV endemic areas such as Africa and East Asia. Hence,
it is expected that the prevalence of HBV in migrants from these countries would be high, considering
the ethnic diversity of the population [4]. Indeed, studies conducted in the Arabian Gulf region
reported HBV seroprevalence to be between 2–7% [5]. Factors that might also lead to a high prevalence
of the HBV infection the MENA region will be discussed below. The prevalence of HBV infection
in different countries in the MENA region according to hepatitis B surface antigen (HBsAg) marker
is summarized in Table 1. A review of recent peer-reviewed literature was conducted in different
databases such as PubMed, Science Direct, Web of Science, and Scopus. Our search strategy utilized
different combinations of search terms, such as ‘pathogenesis’, ‘genotype’, OR ‘HBV’ together with
the name of each Arab country as ‘affiliation’ or ‘title’. Articles were screened based on the title
and abstract. Eligible articles were fully reviewed and screened for the sample size, assay used,
and reported prevalence for all Arab countries.
Table 1. Prevalence of hepatitis B surface antigen (HBsAg) among people in the Middle East and North
Africa (MENA) region using different detection methods.
Country Sample Size Prevalence (%) Diagnostic Assay Used Year Reference
Turkey
101,648 4 Elecysys HBsAg II ELISA (Roche Diagnostics, Germany) 2018 [6]
1404 6.6 micro-ELISA method 2003 [7]
12,010 3.8 ELISA 2013 [8]
30,716 2.2 - 2011 [9]
10,391 8.1 ELISA E170 (Roche, Germany) 2010 [10]
Iran
6583 2.6 Enzygnost HBsAg5.0 kit (Dade Behring, Germany) 2009 [11]
708 0.28 Radim kit (KHB31WB) through immunoenzymometricassay 2010 [12]
284 0.35 ELISA using the EIAgen HBsAg Kit 2011 [13]
124,704 0.24 ELISA 2014 [14]
20,591 0.23 The DIASORIN (Italy) kits 2012 [15]
2,026,628 0.38 Third generation ELISA kits 2014 [16]
Pakistan
7000 2.5 ELISA Abbott Determine (TM) 2010 [17]
11,900 9.8 Immunochromatography technique-based kitcommercially (Determine-Abbott USA). 2011 [18]
127,828 2.68 BEST 2000 ELISA (Biokit, Spain) 2012 [19]
2155 1.34 - 2013 [20]
160,376 2.35 Fourth generation ELISA kits (Bio-kit) 2014 [21]
Afghanistan 330 3.6 Fast cassette kits 2014 [22]
Palestine
146 8.2 ELISA 2014 [23]
17,060 3.8 Abbot EIA 2002 [24]
399 2.8 ELISA 2004 [25]
Jordan 62,933 0.52
Murex HBsAg Version 3 ELISA kit (DiaSorin S.p.A.,
Dartford, UK) or BioRad Monalisa HBsAg sandwich
ELISA kit (Bio-Rad, Marnesla Coquette, France).
2016 [26]
Lebanon 16,084 0.92 Hepanostika HBsAg Uni-Form II, a sandwich ELISA(Biomerieux, Marcy l’Etoile, France) 2006 [27]
Yemen
521 16.9 Monolisa enzyme immune assays (BIO-RAD, France) 2012 [28]
3000 2.1 ELISA 2014 [29]
400 10.8 Fourth generation ELISA 2013 [30]
Iraq
9610 1.6 ELISA 2013 [31]
23,336 0.73 ELISA 2010 [32]
495,648 0.66 ELISA 2011 [33]
Qatar 78,428 0.9 - 2007 [34]
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Table 1. Cont.
Country Sample Size Prevalence (%) Diagnostic Assay Used Year Reference
495 1.0
ELISA (Axsym, Abbott Laboratories) 2006 [35]Oman
604 7.1
UAE 595 1.5
Saudi
Arabia
10,234 5.9 Fourth generation ELISA 2017 [36]
8501 0.7 chemiluminescent microparticle immunoassays(ARCHITECT® HBsAg, ARCHITECT®) 2016 [37]
2807 0.8 ELISA (BioRad, Marnes–la-Coquette, France) 2016 [38]
29,949 3.8 ELISA (Siemens-BEPIII, Dade Behring, Marburg,Germany) 2013 [39]
3192 3 EIA (Abbott Laboratories, Chicago, IL, USA) 2008 [40]
2330 11.8 PCR and agarose gel electrophoresis 2004 [41]
Bahrain 7714 3.7 EIA/ELISA, and reconfirmed by PCR 2004 [41]
Kuwait 12,798 1.92
-Chemiluminescent immunoassays
-Neutralization confirmatory assay (Auszyme
monoclonal, Abbott Laboratories, Abbott Park, IL)
2005 [42]
Egypt
12,000 1.98 ELISA 2013 [43]
308,762 1.22 Enzygnost HBsAg 6.0 2014 [44]
Sudan
5965 9.76 - 2015 [45]
178 21.3 ELISA 2016 [46]
404 11 Enzygnost HBsAg; 5.0 EIA 2011
Morocco 23,578 1.81 Murex HBsAg Version 3 2013 [47]
Libya
65,761 2.2 Third generation microparticle EIA (Axsym) 2013 [48]
1500 1.5 ELISA 2010 [49]
Direct exposure to infected body fluids or blood, unprotected sex, and vertical transmission
are the main routes of HBV transmission [4]. The vertical transmission from an infected mother to
her baby is mainly perinatal. Other routes of viral transmission could be through the shared use of
non-sterile needles, toothbrushes, razors, or medical equipment contaminated with infected blood.
Although HBV is a transfusion-transmissible virus, the risk of transmission through blood transfusions
decreased decades ago due to the implementation of strict safety measures. The symptoms of HBV are
not distinguishable from other hepatitis infections [4]. In addition, many people may not show any
symptoms or even undergo unnoticed (silent) acute or chronic infection. Despite that, Hepatitis B has
different infection stages characterized by the presence of specific biomarkers such as viral antigens,
antibodies against different viral antigens, or viral DNA. Therefore, HBV infection can be detected
serologically by either screening for HBsAg and hepatitis B envelope antigen (HBeAg), or screening for
antibodies against the core protein (anti-HBc) or e antigen (anti-HBe). Most importantly, HBV DNA
and viral load can be detected by polymerase chain reaction (PCR) [2].
This review aims to provide insights into HBV by reviewing recent reports covering HBV genotypes
epidemiology, coinfection with other viruses, serological and molecular detection, in addition to the
viral genetics and host factors associated with HBV pathogenesis. Special attention will be given to the
studies conducted in the Arabian Gulf area and MENA regions.
2. HBV Genotype Distribution and Clinical Relevance
In the Arabian Gulf region, the average prevalence of HBV-infection is reported to be between
2–7%. However, in some countries can reach up to 16.9% and 21.3% such as in Yemen and Sudan,
respectively (Table 1) [5,50]. HBV is the second most common causative agent for HCC in most MENA
countries following hepatitis C virus (HCV) [51,52]. The high prevalence of the HBV infection in the
MENA region could be due to several factors (discussed below) including its genetic variability and
heterogeneity. The genetic variability of HBV might be explained by its genome structure, which
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harbors a reverse transcriptase that facilitates the replication of the viral genomic DNA (Figure 1), due to
the lack of proofreading mechanism of the HBV reverse transcriptase and high viral replication rate,
which is around 1.4–3.6 × 10−5 substitutions per nucleotide site per cell infection [53]. HBV mutation
rates are 100 times higher than other DNA viruses (ranging from DNA 10−8 to 10−6) and almost
similar to RNA viruses (ranging from 10−6 and 10−4) [54,55]. For instance, Peck et al. concluded from
their study that HCV and HIV has almost similar mutation rate as HBV. In addition, due to high
immigration rate in the Arabian Gulf region from different countries in the world, including those of
highly endemic region, this might lead to coinfection with different HBV genotypes and generation of
new hybrid genotypes. In the presence of selective pressure against HBV, caused by immune responses
or antiviral therapies, mutant and hybrid species can survive and dominate. To date, many genotypes
and subtypes have emerged (Figure 2). There are 10 HBV genotypes, distributed across different
geographical regions worldwide (all reviewed in-details in [3]). For instance, genotype A, B, and C are
common in the Asian continent, and viral mutations were frequently associated with genotype C [56].
Genotype A is also highly prevalent in Europe and Africa, while West Africa is known for a restricted
genotype, which is E. On the other hand, genotype D was found to be the most prevalent genotype in
the Middle East. HBV genotypes are distinguished by a divergence in the nucleotide sequence of 8%,
while subtypes under each genotype have a divergence of 4% [57].
  
Pathogens 2019, 8, x; doi: FOR PEER REVIEW www.mdpi.com/journal/pathogens 
 
Figure 1. Schematic representation of the HBV genome. The genome is approximately 3020 nucleotides long 
and consists of partially double-stranded DNA. There are four overlapping open reading frames, four 
promoters, and two enhancer elements to regulate the transcription of viral RNA. The gene S encodes for 
the HBsAg, and it is a long open reading frame containing three start codons. Thus, the gene is divided into 
three sections, pre-S1, pre-S2, and S. The core gene consists of the pre-core and core regions, which encode 
for the HBV e antigen (HBeAg) and core protein, respectively. The polymerase (P) gene overlaps the entire 
S gene and encodes the viral DNA polymerase. Hepatitis B x antigen (HBxAg) is the smallest gene and is 
associated with the activation of transcription. The negative-sense strand is complementary to the viral 
mRNA. Using covalently closed circular DNA (cccDNA) as a template; the viral genes are transcribed by 
the cellular RNA polymerase II in the nucleus. DR1 and DR2 are 11-base-pair direct repeats that are required 
for strand-specific DNA synthesis during the HBV replication. Two enhancers (Enh1 and Enh2) exhibit 
activity in regulating the expression of the complete viral transcripts. 
Figure 1. Schematic representation of the HBV genome. The genome is approximately 3020 nucleotides
long and consists of partially double-stranded DNA. There are four overlapping open reading frames,
four promoters, and two enhancer elements to regulate the transcription of viral RNA. The gene S
encodes for the HBsAg, and it is a long open reading frame containing three start codons. Thus, the gene
is divided into three sections, pre-S1, pre-S2, and S. The core gene consists of the pre-core and core
regions, which encode for the HBV e antigen (HBeAg) and core protein, respectively. The polymerase
(P) gene overlaps the entire S gene and encodes the viral DNA polymerase. Hepatitis B x antigen
(HBxAg) is the smallest gene and is associated with the activation of transcription. The negative-sense
strand is complementary to the viral mRNA. Using covalently closed circular DNA (cccDNA) as a
template; the viral genes are transcribed by the cellular RNA polymerase II in the nucleus. DR1 and
DR2 are 11-base-pair direct repeats that are required for strand-specific DNA synthesis during the
HBV replication. Two enhancers (Enh1 and Enh2) exhibit activity in regulating the expression of the
complete viral transcripts.
Pathogens 2019, 8, 63 5 of 22Pathogens 2019, 8, x FOR PEER REVIEW 2 of 24 
 
 
Figure 2. Worldwide geographic distribution of HBV genotypes. HBV has ten established genotypes that 
have different global and epidemiological distribution. Red color represents countries with high HBV 
prevalence, orange represents countries with moderate HBV prevalence, and yellow are countries with low 
HBV prevalence. Letters represent genotype and sub-genotype prevalent in each country. 
It is believed that genotyping of HBV is important since HBV genotypes differ in terms of disease 
severity and pathogenicity response to interferon treatment. For instance, liver cirrhosis and progression 
to liver cancer are more commonly associated with HBV genotypes C and D compared to other genotypes 
[56]. However, genotype H, which is found in Central America, has lower pathogenicity in comparison to 
other genotypes. The low pathogenicity of genotype H could be attributed to the low viral replication rate 
and the altered expression of envelope proteins compared to genotype D as suggested by Sozzi et al. [58]. 
Moreover, a study aimed to investigate the epidemiological distribution as well as the correlation between 
clinical outcomes and genotypes, showed that genotype D was the most common genotype in Saudi 
Arabia, followed by genotype A, then E. Surprisingly, HBeAg levels were significantly lower in genotype 
D patients’ sera in comparison to those of genotype A and E patients, suggesting that genotype D has a 
better survival and immunoevasion mechanisms than other genotypes independent from high viral 
replication. These findings contradict Sozzi et al. who draw their conclusion based on observations from in 
vitro infection experiments. In regard to progression to liver cancer, the association between HBV genotype 
D infection and developing HCC has been wildly investigated in Egypt [59,60]. A group of researchers 
investigated genotype D through sub-typing and partial sequencing of preS1/preS2 DNA region to 
examine the impact of genetic variability of this region on HCC development [60]. The study concluded 
that HCC was not relevant to genotype D nor preS1/preS2 mutations. 
Genotype D was found to be associated with occult hepatitis B virus infection (OBI) in the MENA 
region. It is a condition in which the level of HBsAg is undetectable with low levels of serum and/or liver 
HBV DNA [61]. In Saudi Arabia, it was found that OBIs prevalence reached 0.2% among blood donors and 
genotype D was predominant [37,62]. Although screening for OBI relies on HBc antibody, this study 
recommended screening blood donors using sensitive molecular testing in addition to HBc antibodies to 
exclude all cases of OBI. Another study conducted in Egypt has also shown similar findings in which OBI 
was associated with genotype D more than other genotypes [63]. Moving to Iran, HBV has been studied 
extensively, and several studies agreed on the predominance of genotype D [63,64]. Similarly, in Oman 
where there is an intermediate prevalence of HBV, a study by Al Baqlani et al. showed that genotypes D 
and A are predominant, followed by C and E, which were less prevalent, represented by a minority of the 
Figure 2. rl i e e graphic distribution of HBV genotypes. HBV has ten established genotypes
that have different global and epidemiological distribution. Red color represents countries with high
HBV prevalence, orange represents countries with moderate HBV prevalence, and yellow are countries
with low HBV prevalence. Letters represent genotype and sub-genotype prevalent in each country.
It is believed that genotyping of HBV is important since HBV genotypes differ in terms of
disease severity and pathogenicity response to interferon treatment. For instance, liver cirrhosis and
progression to liver cancer are more commonly associated with HBV genotypes C and D compared to
other genotypes [56]. However, genotype H, which is found in Central America, has lower pathogenicity
in comparison to other genotypes. The low pathogenicity of genotype H could be attributed to the
low viral replication rate and the altered expression of envelope proteins compared to genotype D as
suggested by Sozzi et al. [58]. Moreover, a study aimed to investigate the epidemiological distribution
as well as the correlation between clinical outcomes and genotypes, showed that genotype D was the
most common ge otype in Saudi Arabia, followed by genotype A, then E. Surprisin ly, HBeAg levels
were significantly lower in genotype D p tient ’ sera in comparison to those of gen type A and E
patients, suggesting that genotype D has a better survival and imm noevasion mechanisms than other
genotypes independent from high viral replication. These findings contradict Sozzi et al. who draw
their conclusion based on observations from in vitro infection experiments. In regard to progression to
liver cancer, the association between HBV genotype D infection and developing HCC has been wildly
investigated in Egypt [59,60]. A group of researchers investigated genotype D through sub-typing
and partial sequencing of preS1/preS2 DNA region to examine the impact of genetic variability of this
region on HCC development [60]. The study concluded that HCC was not relevant to genotype D nor
preS1/preS2 mutations.
Genotype D was found to be associated with occult hepatitis B virus infection (OBI) in the MENA
regi n. It is a conditio in which the level of HBsAg is undetectable with low levels of serum and/ r
liver HBV DNA [61]. In Saudi Arabia, it was found that OBIs prevalence reached 0.2% among blood
donors and g notype D was predominant [37,62]. Although screening for OBI relies on HBc antibo y,
this study recommended screening blood donors using sensitive molecular testing in addition to HBc
antibodies to exclude all cases of OBI. Another study conducted in Egypt has also shown similar findings
in which OBI was associated with genotype D more than other genotypes [63]. Moving to Iran, HBV
has been studied extensively, and several studies agreed on the predominance of genotype D [63,64].
Similarly, in Oman where there is an intermediate prevalence of HBV, a study by Al Baqlani et al.
showed that genotypes D and A are predominant, followed by C and E, which were less prevalent,
represented by a minority of the cases. In addition, the later study highlighted the importance of
sequencing to detect mutations especially in case of antiviral treatment resistance [65]. However,
although a similar study conducted on the Palestinian population also showed that genotype D was
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predominating, yet, this study also showed that genetic variation and mutations in HBV polymerase
gene were unlikely to cause treatment resistance [66]. In summary, it is noticeable that genotype D is
the most common genotype found in the MENA region with few exceptions. For instance, a study
conducted in Egypt highlighted that HBV genotypes genotype E, but not D, was the most prevalent
among healthcare workers [67]. Although there is some evidence, the relationship between genetic
variability and disease progression in the MENA region needs further investigation. However, it seems
that genotype D causes the most severe form of HBV viral hepatitis in the MENA region.
3. HBV Pathogenesis Associated with Host-Virus Interactions
3.1. Host Factors: Genetic Variations
Although HBV genome integration in the host chromosome is not the critical mechanism of HBV
pathogenesis, it was found in certain HCC cases that the generated cccDNA persists as a template
for the transcription of viral RNA that integrates into the host cell and enables the production of
new virions (Figure 3) [68]. Certain host-related factors contribute to these events facilitating HBV
persistence, chronicification, and hepatocarcinogenesis. Some of those factors are general circumstances
of long exposures to damaging chemicals or oxidative species, repair mechanisms impairment and
continuous viral infections [69]. Others include host age during the infection. Early exposure to HBV
permits the virus to persist in infants due to immature immune responses and manifest as chronic later
in life, unlike in adults. For instance, among chronic HBV-positive patients, 28.8% caught the infection
when they were <5 years old, while 7.7% were >30 years old [70]. More specifically, Coursaget et al.
reported that HBV-positive infants, <6 months and between 2–3 years, progress to chronic infection in
82% and 15% of the cases, respectively [71]. Consequently, at HBV transmission, the association of age
with the duration of chronic infection is inverse.   
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by transcription and nuclear export of all viral mRNA to the cytoplasm for translation. The surface protein 
enveloping process occurs in the endoplasmic reticulum and then assembled in the cytoplasm. These 
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nucleocapsid. The different viral components will assemble into new virions that will be released out of the 
host and infect new hepatocyte. 
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receptors, one Tunisian study found significant associations of TLR3 (rs3775290, TT) and TLR4 (rs4986790, 
GG) minor genotypes with higher risks of chronic HBV-infection [72]. Others found that TLR9 (rs187084, 
AA) genotype was related to HBV-persistence among Moroccan patients [73]. As for TNF, multi-functional 
cytokines responsible for cellular activities, TNF-α (rs1800630, -863C/A; rs1800629, -308G/A; rs1800750, -
376G/A; rs1800610, +489G/A) and TNF-b1 (T29C) polymorphisms were thought to increase disease 
susceptibility once seen at high frequencies among Egyptian chronic patients causing decreased cytokine 
secretion [74,75]. Similarly, TNF-α (rs1800629, -308A; rs361525, -238A) and TNF-R2 variable number 
tandem repeat (VNTR) (p75) were remarkably linked together to chronic and progressive HBV-infection 
among Tunisians [76]. Interestingly, one-of-a-kind study in the MENA investigated PD-1 (programmed 
death-1), a crucial checkpoint inhibitor regulating mainly T-cells and other immune cells, and its possible 
association with host-response to HBV focusing on rs10204525 multi-genotypes. They found that genotype 
AA at this allele (rs10204525) was protective against the infection, while GG and GA genotypes increase 
the risk to develop a chronic infection among Moroccans specifically, and possibly Mediterranean [77]. In 
regards to HLA genes, encoding for MHC and responsible for immune responses, a Saudi study inspecting 
the link of HLA polymorphisms to HBV-infection, revealed that variations in HLA-DP (rs3077; rs9277535) 
and HLA-DQ (rs2856718; rs9275572) were significantly correlated to HBV-infection, mostly in chronic 
Figure 3. Schematic presentation of the HBV lif cycle. HBV attac s to t host h patocyte cell
membran through its envelope prot ins. Wh n the viral membrane fuses with the cell membrane,
it w ll result in releasing the viral g nome into the cell cytoplasm. After th viral genome reaches the
nucl us, the viral polymerase enzyme will c nv rt the partially double-stranded DNA genome into
cccDNA. This is follow d by transcription and nuclear export of all viral mRNA to the cytoplasm for
translation. The surface protein veloping process occurs in the endoplasmic reticulum nd then
assembled in the cytoplasm. These proteins ar transported t the post-endoplasmic reticulum and
Golgi compartments for the budding of the nucleocapsid. The different viral components will assemble
into new virions that will be released out of the host and infect new hepatocyte.
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Additionally, human genes polymorphisms have been reported worldwide to contribute to host
susceptibility to chronic HBV and HBV-clearance, of which, IL-4, CTLA4, TLR, TNF, HLA genes,
etc. Few studies drew attention to such interest in the MENA region. Starting with TLR, important
innate cells receptors, one Tunisian study found significant associations of TLR3 (rs3775290, TT) and
TLR4 (rs4986790, GG) minor genotypes with higher risks of chronic HBV-infection [72]. Others found
that TLR9 (rs187084, AA) genotype was related to HBV-persistence among Moroccan patients [73].
As for TNF, multi-functional cytokines responsible for cellular activities, TNF-α (rs1800630, −863C/A;
rs1800629, −308G/A; rs1800750, −376G/A; rs1800610, +489G/A) and TNF-b1 (T29C) polymorphisms
were thought to increase disease susceptibility once seen at high frequencies among Egyptian chronic
patients causing decreased cytokine secretion [74,75]. Similarly, TNF-α (rs1800629, −308A; rs361525,
−238A) and TNF-R2 variable number tandem repeat (VNTR) (p75) were remarkably linked together to
chronic and progressive HBV-infection among Tunisians [76]. Interestingly, one-of-a-kind study in
the MENA investigated PD-1 (programmed death-1), a crucial checkpoint inhibitor regulating mainly
T-cells and other immune cells, and its possible association with host-response to HBV focusing on
rs10204525 multi-genotypes. They found that genotype AA at this allele (rs10204525) was protective
against the infection, while GG and GA genotypes increase the risk to develop a chronic infection
among Moroccans specifically, and possibly Mediterranean [77]. In regards to HLA genes, encoding for
MHC and responsible for immune responses, a Saudi study inspecting the link of HLA polymorphisms
to HBV-infection, revealed that variations in HLA-DP (rs3077; rs9277535) and HLA-DQ (rs2856718;
rs9275572) were significantly correlated to HBV-infection, mostly in chronic patients [78]. Moreover,
a significant association of a single-nucleotide polymorphism (SNP) near FDX-1 (Ferredoxin-1 gene on
chromosome 11) with chronic infection was displayed, making this SNP at 11q22.3 a risk allele among
Saudi patients [79]. Recently, the same investigators studied the effect of microRNAs variations on host
responses. They concluded that, among 10-targeted SNPs in Saudi patients, eight were linked to either,
some or all HBV clinical stages (susceptibility, persistence, progression, and clearance). In particular,
miR-30a rs1358379 was correlated to all stages. miR-149 rs2292832 and miR-196a2 rs11614913 were
correlated to HBV-susceptibility, disease clearance, and progression to HCC/cirrhosis. miR-146a
rs2910164 was related to HBV-susceptibility and -clearance and miR-423 rs6505162 was related to viral
progression and clearance. miR-492 rs2289030 was uniquely linked to HBV-clearance, while miR-26a1
rs7372209 and miR-608 rs4919510 were uniquely linked to HBV-progression [80]. In comparison to
other population-specific SNPs, a review by Akcay et al. collected and summarized worldwide GWAS
in an attempt to recognize the role of host polymorphism in HBV-infection, in which HLA topped the
list of most related SNPs to HBV pathogenesis and persistence [81]. Overall, researchers in the region
are in the right track to identify specific local variations associated with HBV-disease, yet, more studies
are needed in this field. Nevertheless, SNPs found amongst indigenous populations in the MENA
region need to be confirmed in larger samples, generalized to specific ethnic groups, and integrated
into reference databases at the regional and international level.
3.2. Viral Factors
3.2.1. Viral Precore (HBeAg) and Core (HBcAg) Mutations
All hepadnaviruses share the expression of the pre-core gene product, HBe. This antigen is expressed
in infected cells as a modified secreted form of HBcAg [82]. The core protein is highly immunogenic,
making it the main target for viral clearance by host immunity. The role of HBcAg is stimulating
Th1 immune response, while HBeAg can stimulate both Th1 and Th2 phenotypes to tolerate host
immune responses towards HBcAg [83]. Introducing frameshift or point mutations into the pre-core
gene could suppress HBeAg expression [84], which is associated with the diminished capability to
cause persistent infection [85]. The most common mutation reducing HBeAg levels is a nonsense
G1896A, found at pre-core codon region [86], thus preventing HBeAg expression in most cases through
stopping pre-core mRNA transcription. Since G1896A nonsense mutation terminates HBeAg, it is
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frequently found among HbeAg-negative individuals. However, in certain cases, G1896A could also
be found in HBeAg-positive individuals in the MENA region. For instance, Ayari et al. found that
G1896A mutation was found one out of six Tunisian patients who was HBeAg-positive [87]. Viruses
acquire such mutation during persistence to escape host anti-HBe-antibodies, and to create an RNA
loop interacting with DNA-polymerase enhancing HBV-replication in each genotype differently [88].
G1896A varies in abundance among HBV genotypes and geographic areas, with genotype A being the
least-reported worldwide. In the MENA region, G1896A was reported at high-frequency in Tunisian
HBV-patients, mostly in HBeAg-negative compared to HBeAg-positive individuals [87]. Interestingly,
the prevalence of this mutation was elevated in genotype E compared to genotype D as previously
reported in [87,89]. Likewise, this mutation was reported in UAE and was prevalent in genotype
D-carriers [90]. Meanwhile, in Saudi Arabia, precore W28X and G29D were significantly linked to
infection progression to cirrhosis/HCC [91].
As for core gene, most common mutations are A1762T and G1764A, which occur in covalently at
the promoter. These mutations are reported to affect pre-core RNA transcription, and therefore result in
reduced HBe production [92]. Decreased HBeAg expression is not influenced by those mutations only,
further positions at the core gene have been linked to this consequence if mutated, such as 1753,
1757, 1766, and 1768 [93]. Furthermore, mutations mentioned above augment genome replication,
increasing HBcAg levels by >10-folds compared to wild HBV types via pgRNA up-regulation [93].
In contrast to precore mutations prevalence, core mutations are more common among HBV genotype
A, B, and C compared to genotype D [94]. The aforementioned MENA countries reported core
mutations in their studies. A1762T/G1764A double mutation was reported among Tunisian population,
in HBeAg-positive patients more than -negative ones [87], and in UAE among genotype A and D
patients [90]. In Saudi Arabia, >35 core mutations were examined, and only six were significantly
correlated to HBV progression (i.e., F24Y, E64D, E77Q, A80I/T/V, L116I, and E180A), through changing
specific HBcAg immunogenic epitopes to escape B-cells and T-cells neutralization [91].
3.2.2. Viral PreS/S (HBsAg) Mutations
HBsAg, an expressed protein on the surface of the virus, is one of the early viral markers for HBV
active or acute infection [95]. HBsAg level in the serum is associated with cccDNA levels inside host
hepatic cells, defining a clinical relevance of this marker [96]. For that, HBV-infection can be indirectly
assessed by quantifying levels of circulating HBsAg to determine the infection history, status of
HBV-infected patients (e.g., inactive carriers, chronic, or reactive patients) and treatment outcomes [88].
Similar to HBcAg, HBsAg is highly immunogenic and able to trigger the activation of CD8+ T-cells
by dendritic cells (DCs) and macrophages antigen presentation without inflammatory cytokines
involvement [97]. In some chronic patients though, HBsAg can inhibit cytokine production of DCs and
macrophages through Toll-like receptors (TLR) signalling and can manipulate innate responses [98].
While in other chronic patients, HBsAg can trigger HBV-specific T-cells through antigen presentation
of macrophages [99]. Introducing deletion or point mutations at certain PreS regions have been linked
to HCC development [100]. Whether located in C- or/and N-terminus regions of PreS1 or/and PreS2,
the main consequence of those mutations is the production of short forms of HBsAg, affecting T-cells
and/or B-cells recognition sites and thus escaping adaptive immune system [82]. Moreover, mutant
full-length HBsAg can induce oxidative stress and replication impairment of host cells, degrade
a cyclin-dependent kinase inhibitor (cell-cycle inhibitor) p27 and trigger cell transformation [101].
Most prevalent genotypes with mutant HBs are mainly genotypes C and B, isolated from chronic
patients and related to chronic infection and HCC formation [102]. In MENA region, P127S/T, an escape
mutation, P120T, responsible for low HBsAg expression in-vitro, Y134F and S143L mutations were
detected in chronic HBV Egyptian patients and reported mostly in genotypes B and D (subgenotype
D3/D7) [103,104]. F130L and S135F mutations were found in Saudi patients carrying genotype D
(subgenotypes D1/D3), with unknown effect to HBsAg and unknown association to the disease
pathogenesis [105]. In Palestine, reported mutations in this gene were T126T, P127S, G145R, and D144E
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escape mutations among HBV genotype D (subgenotype D1) HBsAg-positive patients [66]. Lastly,
in Tunisia, the most abundant mutation out of many detected ones was S143L/T, which was prevalent
among genotype D (subgenotype D7) carriers and significantly related to viral progression to cirrhosis.
Most substitutions belonged to T-helper, T-cytotoxic, and B-cells epitopes, in an attempt to decrease
viral–host binding affinity [106].
3.2.3. Viral X Gene (HBxAg) Mutations
HBx gene is a small gene producing a short conserved protein among all hepadnaviruses [107].
Its main functions are dormant cell activation and HBV promoters’ stimulation through transcription
factors or signaling pathways [107]. HBx has been connected to cell apoptosis through Ca2+
signaling causing elevated oxidative stress [108]. Moreover, the latter can ensure infected liver
cells survival, through blocking TNF-α and activating NF-kB, promoting persistent HBV-infection [109]
and consequently HCC formation through PYK2 and SRC pathways [110]. These findings might
clarify the relationship of HBx to severe chronic liver damage. Introducing mutations at certain x gene
regions and overlapping with core gene at 1753, 1762, 1764, and 1768 positions, result in C-terminal
alteration of HBxAg, which inhibit cell replication to an extent and p21 expression [111]. In MENA
countries, only Saudi Arabia reported mutations in this gene, such as I127T, V131I, F132Y/I/R, H94Y,
and K130M mutations. These variations were significantly linked to severe infection and progression to
HCC. Once K130M+V131I, with/without a third mutation, were found together the risk of developing
HCC increased more compared to single mutation cases [112]. One year later, similar investigators
conducted functional analysis research for some of these mutations along with other deletion mutations.
They found that full-length (1–154) and short-length versions (1–94; 31–152; 61–154; 61–124) of HBx
were affecting cell cycle through p53 inhibition by truncated forms and through p27, p21, and cyclin
D1 overexpression by complete form. Notably, C-terminal and N-terminal deletions of HBx were
in favour of the protein’s oncogenic property, and in favour of check-point inhibitor overexpression,
respectively [113].
In Summary, further mutational analysis is needed to reveal the role of reported mutations and
the affected pathways. Moreover, deeper inspection of mutant viruses circulating in MENA countries
in correlation to their genotypes’ prevalence and the clinical disease stages.
4. HBV Coinfections
Coinfection of hepatitis B patients with HCV, human immunodeficiency virus (HIV), hepatitis
E virus (HEV), torque teno virus (TTV) and human pegivirus (HPgV), formerly known as GB virus
C/hepatitis G virus (GBV-C/HGV), has already been reported [114,115]. However, prevalence, viral
interactions and clinical significance of such coinfections are yet to be fully elucidated, particularly in
the MENA region. McArdle et al. [116] stated that viral coinfections could give rise to insignificant,
deleterious or beneficial effects in patients by altering normal host response, changing diagnostic tests
performance, and modulating host responses to treatment [116]. These possibilities will be further
explored in the context of HBV coinfection with each of HCV, HIV, HEV, TTV and HPgV (GBV-C/HGV).
4.1. HCV/HBV Coinfections
As previously mentioned, OBI refers to HBV infections that are “serologically silent”. This is
characterized by having low levels of serum and/or liver HBV DNA with undetectable serum
HBsAg [117]. This virologic phase is seen in HBV-patients with HCV superinfection in Mediterranean
Basin and Far East Asian countries with a prevalence of 33% and 50%, respectively [118]. Some studies
argue that HCV superinfections suppress HBV replication in patients with HCV/HBV coinfection [117],
resulting in undetectable serum HBsAg levels seen in occult HBV virologic phase. Furthermore,
in HCV/HBV coinfected-patients with occult HBV, clearance of HCV using pegylated interferon-α
(peg-IFN-α) and ribavirin resulted in HBV-reactivation, further supporting the hypothesis that HBV
replication is suppressed by HCV [119]. However, since occult HBV is not always accompanied by HCV
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coinfection, Fukuda et al. argue that other factors, such as the 8-nt mutation in HBV promoter, could be
responsible for reduced HBV replication seen in occult HBV [120]. On the other hand, an HCV/HBV
coinfection is deemed clinically significant as it results in higher morbidity rates than a single HBV
infection. Fong et al. reported that higher rates of liver cirrhosis are observed in coinfected patients as
compared to those with a single HBV-infection (44% vs. 21%) [121]. The same study also reported an
increased prevalence of the decompensated liver disease in patients with dual infection (24% vs. 6%).
Similarly, one longitudinal study shows that the cumulative risk of developing HCC is higher in
patients with a double infection than in patients with an HBV mono-infection (45% vs. 16%) [122].
Therefore, Donato et al. suggested a synergistic interaction between both viruses in causing HCC
where HBV initiates the neoplastic process, and HCV consequently acts as a promoter, thus worsening
the liver status of coinfected individuals [123].
4.2. HIV/HBV Coinfections
HIV/HBV coinfections are by far one of the most explored coinfections due to their high prevalence.
This is mostly attributed to the viruses having shared modes of transmission, i.e., sexual and
percutaneous routes. In HIV-infected populations, HBV coinfection rates could reach 25% in countries
where the viruses are endemic, and >10% in Northern Asia and other countries where HBV is not
prevalent [124]. This rate varies according to geographical locations and modes of acquiring the
infection. For instance, HBV/HIV infections were found to not exceed 1.5% in Egypt, KSA, and
Turkey [125–127]. The mode of transmission also appears to play a role where men who have sex
with men (MSM) were found to have the highest rates of coinfection as compared to heterosexuals
and injecting drug users (IDUs) [124]. Considering that HBV is around 100-times more likely to be
acquired than HIV, HBV infections typically precede HIV infections [124].
The clinical challenges imposed by this coinfection is found to be similar to those of an
HCV/HBV coinfection where dual infections result in higher liver-related mortalities than single
HBV infections [128]. Studies showed that patients with dual infection were significantly more
probable to be HBeAg sero-reactive as compared to patients with HBV mono-infection (37% vs. 10%).
These patients were also found to have higher HBV viremia (≥4.3 log IU/mL) than mono-infected
individuals (37% vs. 16%) [129]. Studies by Kourtis et al. found that progression to chronic hepatitis B is
around five-fold quicker in coinfected individuals as compared to HBV mono-infected individuals [130].
4.3. TTV/HBV Coinfections
Throughout the MENA region, HBV-coinfection with TTV appears to be a common occurrence
with percentages ranging from 31.3% [131] in Turkey to 90.7% [132] and 88.8% [133] in Qatar
and KSA, respectively. When the effect of this coinfection was evaluated through the measurement
of serum ALT levels, studies found no significant TTV-induced biochemical response in coinfected
individuals [115,133]. Studies carried out in Egypt also found the prevalence of HCC and liver cirrhosis
in patients with the HBV/TTV coinfection to be of no statistical significance when compared with
groups without the coinfection [134]. On the contrary, the histological liver investigation of 25 pediatric
patients with chronic hepatitis B revealed that those with TTV viremia had a significantly higher
histologic activity index, periportal necrosis, as well as portal inflammation scores than those with
a simple HBV infection. Kasirga et al. also reported that HBV infected individuals are significantly
more likely to harbour a TTV infection suggesting a possible shared route of transmission between
the two viruses [135]. This finding contrast with the findings from our lab, we reported no significant
difference between the two groups mentioned earlier [132]. The relatively high omnipresence of TTV
in healthy blood donors, particularly in the MENA region, raises questions regarding the clinical and
pathologic significance of an HBV/TTV coinfection [132,136].
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4.4. HEV/HBV Coinfection
The prevalence rate of HEV/HBV coinfections appears to vary greatly in the MENA region with
rates ranging from 0% to 56% [137,138]. Although HEV can be transmitted both vertically and through
blood transfusions, the virus is mainly transmitted through the faecal–oral route due to poor sanitation
conditions [139]. This variation in transmission modalities could account for the differences in the
rates of coinfections in the MENA region. Since HEV is a causative agent of acute and chronic liver
inflammation [140], it is expected for an HEV/HBV coinfection to have significant clinical outcomes.
However, a clear link between these two viral infections is yet to be established [141], Studies done by
Hoan et al. reported the seroprevalence of HEV to be significantly higher in hepatitis B patients than
in controls (45% vs. 32%, P = 0.034) [142]. The same group also found coinfected patients with liver
cirrhosis to have a higher anti-HEV IgM prevalence than patients without liver cirrhosis (16.8% vs.
9.5% P = 0.01) suggesting a correlation between an HEV superinfection and liver cirrhosis in HBV
infected individuals [142].
4.5. HPgV/HBV Coinfection
The prevalence of HPgV infection in HBV infected patients around the MENA region are
relatively comparable with rates of 4.1%, 7.8%, 10.7%, and 12% in KSA, Turkey, Qatar, and Iran
respectively [131,136,143,144]. Studies conducted by Fiordalisi et al. [145] and Yoshiba et al. [146]
reported HPgV to be associated with non-A-E hepatitis. In contrast, a study from our lab reported
that there is no correlation between HBV and HPgV infection [136]. Similarly, Laskus et al. [147] and
Alter et al. [148] reported that the virus does not appear to be hepatotropic as it does not replicate in
hepatocytes nor was it found to cause chronic or acute hepatitis. This is in concordance with studies
investigating the effect of an HPgV and HBV coinfection on the liver where the mean ALT level of
patients with the coinfection was significantly lower than those with a single HBV infection [149].
Studies by Kao et al. showed that HPgV superinfection in HBV infected patients did not cause a
significant change in HBV DNA levels unlike HCV superinfection [150]. HPgV hence does not seem to
mimic the synergistic interaction of HCV/HBV coinfections. Therefore, HPgV superinfection might not
worsen disease status, at least not in the context of the liver. However, data-addressing HPgV in HBV
infected patients is scarce, and so the clinical significance of the coinfection remains poorly understood.
5. Laboratory Diagnosis of HBV
HBV infection is considered a significant global health threat. Accurate diagnosis of HBV infection
is crucial for treatment. There are several stages of HBV infection, where each is characterized by the
presence of specific biomarkers such as viral DNA or human antibodies against viral antigens (Figure 4).
Therefore, detection techniques are classified into serological assays with different sensitivities and
specificities (Table 2) as well as molecular assays for HBV DNA detection using different forms of PCR.
These tests might help recognize the onset and stage of HBV infection. Indeed, if both serological and
molecular techniques are combined, they will add substantial value toward an accurate diagnosis of
HBV infection.
HBsAg is the first detectable marker in serum during the acute infection [95], and its prevalence
in the MENA region has been summarized in Table 1. Laboratory diagnosis of HBV infection in the
MENA region has been mostly based on HBsAg detection. However, since the HBsAg level could be
lower than the detection limit, or present with mutations in the antigen epitopes, molecular techniques
have been considered as an important tool for efficient and accurate HBV detection in several countries
in MENA regions. The molecular methods are useful in quantifying the viral load, genotyping,
and detecting drug resistance mutations [151]. Molecular techniques include amplifying of HBV
DNA using thermal cycling-based techniques such as polymerase chain reaction (PCR), transcription
mediated amplification (TMA), loop-mediated isothermal amplification (LAMP), and rolling circle
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amplification (RCA), etc. Each method has advantages and disadvantages that promote or limit their
use in clinical diagnosis.
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Table 2. Sensitivity and specificity of different commercial immunoassays mostly used for
HBV detection.
Company name Coating Biomarker detected Sensitivity(%)
Specificity
(%) Sample size Reference
Elecsys® HBsAg
II assay
Anti-HBsAg HBsAg 100% 99.97% 9084 [152]
Architect
- HBcAb 79.90% 98%
260 [153]- HBsAg and HBcAb 100% 90%
Elecsys - HBcAb 78.90% 90.20%
Hepalisa
Direct sandwich ELISA,
microwell plates coated
with Anti- HBsAg
HBsAg 100% 100%
100 [154]Microscreen
HBsAg
Microwell plates coated
with Anti- HBsAg 100% 97.8%
ERBA LISA
HEPATITIS B
Sandwich ELISA,
microwell plates coated
with Anti- HBsAg
100% 100%
HEPACARD
Immunochromatographic
assay, membrane coated
with Anti-HBsAg
HBsAg
100% 100% 100 [154]
Crystal HBsAg
SD BIOLINE
HBsAg
Due to slight modifications of conventional PCR in detecting the desired gene sequence, several
forms of PCR have been introduced [140]. Since automated real-time PCR has a high capacity to detect
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a broad range of viral load and lack carry-over contamination, it is considered the standard method for
detecting and quantifying HBV DNA [151]. Other types of PCR that have been used for HBV diagnosis
include multiplex and droplet digital PCR (ddPCR). ddPCR is one example of modern molecular
testing, and it was found to be a sensitive method to detect cccDNA in HBV samples. The HBV
genome is a partially double-stranded DNA that encodes four overlapping genes (Figure 1). The serum
HBsAg can be quantified by molecular assays such as the Elecsys HBsAg II Quant (Roche Diagnostics,
Penzberg, Germany) [155] and Architect HBsAg QT (Abbott Laboratories, Rungis, France) [156].
The advantages of these assays are their ability to detect all forms of circulating HBsAg as well as they
are fully automated with a high throughput capacity as well as low cost. PCR based methods are the
most practised techniques, yet, other methods such as TMA, LAMP, and RCA have been employed
to detect and quantify HBV DNA. However, false-positive results and contamination are the major
drawbacks of the amplification-based assays, which can be avoided by following precautions as well as
the use of proper controls. Another molecular diagnostic method is genotyping by direct sequencing
of HBV DNA, which is useful for studying viral mutations and genotypes. However, this technique is
not adapted to high-throughput screening and is found to be labour-intensive, and time-consuming.
Combining both serological and molecular methods would improve the early detection of the virus
and diagnose the infection more accurately [140].
6. Conclusions
HBV is a highly prevalent virus where 257 million people are living with this infection worldwide.
In the Gulf region, HBV infection rates reached up to 20% and it is considered the second most
common causative agent of HCC following HCV. Genetic variability in the HBV genome resulted
in ten genotypes distributed across different geographical regions worldwide, where genotype D is
the most abundant HBV genotype in the MENA region. HBV pathogenesis and severity of infection
depend on several host and viral factors, particularly, the genetic variability of both, the host and
virus as discussed previously. Although the symptoms of HBV infection are not distinguishable
from other hepatitis infections, there are different clinical stages characterized by the presence of
specific biomarkers. Therefore, combining both serological and molecular methods would improve the
early detection and accurate diagnose of HBV. The incidence and prevalence of HBV infection have
sharply declined in the MENA region due to the implementation of safety measures and effective
universal vaccination programs. Still, the transmission of HBV in some developing countries remains
a significant risk because of the limited access to personal protective equipment and HBV vaccination.
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References
1. Al-Sadeq, D.W.; Majdalawieh, A.F.; Nasrallah, G.K. Seroprevalence and incidence of hepatitis E virus among
blood donors: A review. Rev. Med. Virol. 2017, 27, e1937. [CrossRef]
2. CDC. Hepatitis B. Available online: https://www.cdc.gov/hepatitis/hbv/bfaq.htm#overview (accessed on
1 January 2019).
3. Shen, T.; Yan, X.-M. Hepatitis B virus genetic mutations and evolution in liver diseases. World J.
Gastroenterol. WJG 2014, 20, 5435. [CrossRef]
4. World Health Organization. Hepatitis B. Available online: www.who.int/news-room/fact-sheets/detail/
hepatitis-b (accessed on 1 January 2019).
5. Gasim, G.I. Hepatitis B virus in the Arab world: Where do we stand? Arab J. Gastroenterol. 2013, 14, 35–43.
[CrossRef]
6. Igde, F.; Taskin, H.; Igde, M.; Yazici, Z.; Atilla, A. Where we are in the fight against Hepatitis B Infection;
Trends in Hepatitis B virus seroprevalence in Black Sea Region of Turkey. Niger. J. Clin. Pract. 2018, 21, 87–92.
7. Erden, S.; Büyüköztürk, S.; Calangu, S.; Yilmaz, G.; Palanduz, S.; Badur, S. A study of serological markers of
hepatitis B and C viruses in Istanbul, Turkey. Med. Princ. Pract. 2003, 12, 184–188. [CrossRef] [PubMed]
8. Karatekin, G.; Kilinç, M.; Oksuz, B.G.; Igde, M. Hepatitis B seroprevalence in children and women and the
impact of the hepatitis B vaccination program in the Black Sea Region of Turkey. J. Infect. Dev. Ctries. 2013, 7,
960–965. [CrossRef]
9. Öner, S.; Yapici, G.; S¸as¸maz, C.T.; Kurt, A.Ö.; Bug˘dayci, R. Hepatitis B, hepatitis C, HIV, and VDRL
seroprevalence of blood donors in Mersin, Turkey. Turk. J. Med. Sci. 2011, 41, 335–341.
10. Kangin, M.; Turhanoglu, M.; Gulsun, S.; Cakabay, B. Seroprevalence of hepatitis B and C among children in
endemic areas of Turkey. Hepat. Mon. 2010, 10, 36–41.
11. Merat, S.; Rezvan, H.; Nouraie, M.; Jamali, J.; Assari, S.; Abolghasemi, H.; Radmard, A.-R.; Zaer-Rezaii, H.;
Zeid-Abadi-Nejhad, M.; Hosseini, M.-R. The prevalence of hepatitis B surface antigen and anti-hepatitis B
core antibody in Iran: A population-based study. Arch. Iran. Med. 2009, 12, 225–231. [PubMed]
12. Hashemi, S.; Moghadami, M.; Lankarani, K.; Alborzi, A.; Mahbudi, A. The efficacy of hepatitis B vaccination
among school age children in Southern Iran. Iran. Red Crescent Med. J. 2010, 12, 45–48.
13. Fathimoghaddam, F.; Hedayati-Moghaddam, M.R.; Bidkhori, H.R.; Ahmadi, S.; Sima, H.R. The prevalence
of hepatitis B antigen-positivity in the general population of Mashhad, Iran. Hepat. Mon. 2011, 11, 346.
[PubMed]
14. Aghamohamad, A.; Montazeri, M.; Akbari, M. Prevalence of hepatitis B and hepatitis C in blood donors at
Semnan province from 2008 to 2011. Koomesh 2014, 15, 162–167.
Pathogens 2019, 8, 63 15 of 22
15. Bozorgi, S.H.; Ramezani, H.; Nooranipour, M.; Ahmadi, M.; Baghernejad, A.; Mostajeri, A.; Kargar-Fard, H.;
Sadri, M.; Alavian, S.M. Risk factors of viral hepatitis: Yet to explore. Transfus. Apher. Sci. 2012, 47, 145–149.
[CrossRef]
16. Mohammadali, F.; Aliheidari, S.; Mirrezaie, S.; Hajibeigi, B. Changes In Frequency Of Hbv, Hcv, Hiv And
Syphlis Infections Which Removed From Blood Supply In Tehran Blood Donations 2005: P-279-: P-2792010:
P-279. Vox Sang. 2013, 105, 162.
17. Qureshi, H.; Bile, K.; Jooma, R.; Alam, S.; Afrid, H. Prevalence of hepatitis B and C viral infections in Pakistan:
Findings of a national survey appealing for effective prevention and control measures. East. Mediterr. Health J.
2010, 16, S15–S23. [CrossRef]
18. Sheikh, N.S.; Sheikh, A.S.; Sheikh, A.A.; Yahya, S. Sero-prevalence of hepatitis B virus infection in Balochistan
Province of Pakistan. Saudi J. Gastroenterol. Off. J. Saudi Gastroenterol. Assoc. 2011, 17, 180. [CrossRef]
19. Attaullah, S.; Khan, S.; Khan, J. Trend of transfusion transmitted infections frequency in blood donors:
Provide a road map for its prevention and control. J. Transl. Med. 2012, 10, 20. [CrossRef]
20. Chaudhry, M.A.; Malik, J.R.; Ashraf, M.Z. Seropositivity of Hepatitis B and C in Blood Donors at CMH
Lahore, Pakistan. In Proceedings of the 2014 Asia-Pacific Microwave Conference (APMC 2014), Sendai,
Japan, 4–7 November 2014; pp. 1–5.
21. Zaheer, H.; Saeed, U.; Waheed, Y.; Karimi, S.; Waheed, U. Prevalence and trends of hepatitis B, hepatitis
C and human immunodeficiency viruses among blood donors in Islamabad, Pakistan 2005–2013. J. Blood
Disord. Transfus. 2014, 5, 217–222.
22. Tanju, I.A.; Levent, F.; Sezer, R.G.; Cekmez, F. Hepatitis B, hepatitis C and human immunodeficiency virus
seropositivity among children in kabul, afghanistan: A cross-sectional study. Hepat. Mon. 2014, 14, e16154.
[CrossRef]
23. Dumaidi, K.; Al-Jawabreh, A. Prevalence of occult HBV among hemodialysis patients in two districts in the
northern part of the West Bank, Palestine. J. Med. Virol. 2014, 86, 1694–1699. [CrossRef]
24. Yassin, K.; Awad, R.; Tebi, A.J.; Queder, A.; Laaser, U. Prevalence and risk factors of HBsAg in Gaza:
Implications for prevention and control. J. Infect. 2002, 44, 252–256. [CrossRef]
25. Astal, Z.; Dhair, M. Serologic evaluation for hepatitis B and C among healthcare workers in Southern Gaza
Strip (Palestine). Iug J. Nat. Stud. 2015, 12, 153–164.
26. Souan, L.; Tout, F.; Siag, M.; Sughayer, M.A. Seroprevalence rates of transfusion-transmitted infections
among blood donors in Jordan. J. Infect. Dev. Ctries. 2016, 10, 377–383. [CrossRef]
27. Irani-Hakime, N.; Musharrafieh, U.; Samaha, H.; Almawi, W.Y. Prevalence of antibodies against hepatitis
B virus and hepatitis C virus among blood donors in Lebanon, 1997–2003. Am. J. Infect. Control 2006, 34,
241–243. [CrossRef]
28. Sallam, T.; Raja‘a, Y.; Bahaj, S.; Al-Shami, A.; Lu, M.; Roggendorf, M.; Tong, C. Hepatitis B virus carrier rate,
prevalence and susceptibility and impact of immunization program among households in the city of Taiz,
Yemen. Vaccine 2012, 30, 5564–5568. [CrossRef] [PubMed]
29. Alodini, A.Q. Prevalence of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections among blood
donors at Al-Thawra Hospital Sana’a City-Yemen. Yemeni J. Med. Sci. 2012, 6, 16–20.
30. Murad, E.A.; Babiker, S.M.; Gasim, G.I.; Rayis, D.A.; Adam, I. Epidemiology of hepatitis B and hepatitis C
virus infections in pregnant women in Sana’a, Yemen. BMC Pregnancy Childbirth 2013, 13, 127. [CrossRef]
[PubMed]
31. Tarky, A.; Akram, W.; Al-Naaimi, A.; Omer, A. Epidemiology of viral hepatitis B and C in Iraq: A national
survey 2005–2006. Zanco J. Med. Sci. 2013, 17, 370–380. [CrossRef]
32. Al–Juboury, A.W.; AL-ASSADI, M.K.; Ali, A.M. Seroprevalence of Hepatitis B and C among blood donors in
Babylon Governorate-Iraq. Med. J. Babylon 2010, 7, 121–129.
33. Ataallah, T.M.; Hanan, K.A.; Maysoun, K.S.; Sadoon, A.A. Prevalence of hepatitis B and C among blood
donors attending the National Blood Transfusion Center in Baghdad, Iraq from 2006–2009. Saudi Med. J.
2011, 32, 1046–1050.
34. Fawzi, Z.; Al Hilali, A.; Al Malki, A.; Al Matawa, H.; Yousef, B.; Ali Bin Ali, A.; Al Mansour, S. Survey of
hepatitis markers among donors in the State of Qatar. Qatar Med. J. 2007, 16, 47–50. [CrossRef]
35. Al Awaidy, S.; Abu-Elyazeed, R.; Al Hosani, H.; Al Mulla, A.; Al Busaiedy, S.; Al Amiry, A.; Farah, Z.;
Al Marrie, A.; Bock, H.L.; Al-Shaar, I. Sero-epidemiology of hepatitis B infection in pregnant women in
Oman, Qatar and the United Arab Emirates. J. Infect. 2006, 52, 202–206. [CrossRef] [PubMed]
Pathogens 2019, 8, 63 16 of 22
36. Al Humayed, S.; El-Mekki, A.; Mahfouz, A. Hepatitis B virus infection in Aseer Region, south-western
Saudi Arabia: A call for an immediate action against a preventable disease. Public Health 2017, 146, 24–28.
[CrossRef]
37. Alshayea, A.I.; Eid, G.E.; El-Hazmi, M.M.; Alhetheel, A.F. Prevalence and characterization of occult hepatitis
B infection among blood donors in central Saudi Arabia. Saudi Med. J. 2016, 37, 1114. [CrossRef]
38. AlMutairi, H.H.; AlAhmari, M.M.; Al-Zahran, B.H.; Abbas, I.S.; Al Ghamdi, J.S.; Rajaa, Y.A.; Sallam, T.A.
Prevalence of serological markers and nucleic acid for blood-borne viral infections in blood donors in
Al-Baha, Saudi Arabia. J. Infect. Dev. Ctries. 2016, 10, 619–625. [CrossRef] [PubMed]
39. Abdullah, S.M. Prevalence of hepatitis B and C in donated blood from the jazan region of saudi arabia.
Malays. J. Med. Sci. MJMS 2013, 20, 41–46.
40. El Beltagy, K.E.; Al Balawi, I.A.; Almuneef, M.; Memish, Z.A. Prevalence of hepatitis B virus markers among
blood donors in a tertiary hospital in Tabuk, northwestern Saudi Arabia. Int. J. Infect. Dis. 2008, 12, 495–499.
[CrossRef] [PubMed]
41. Qadi, A.A.; Tamim, H.; Ameen, G.; Bu-Ali, A.; Al-Arrayed, S.; Fawaz, N.A.; Almawi, W.Y. Hepatitis B and
hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: A survey by serologic and
molecular methods. Am. J. Infect. Control 2004, 32, 493–495. [CrossRef]
42. Ameen, R.; Sanad, N.; Al-Shemmari, S.; Siddique, I.; Chowdhury, R.I.; Al-Hamdan, S.; Al-Bashir, A.
Prevalence of viral markers among first-time Arab blood donors in Kuwait. Transfusion 2005, 45, 1973–1980.
[CrossRef]
43. Habil, F.E.; Mahdi, W.K.; Abdelwahab, S.F.; Abdel-Hamid, M. Hepatitis B virus genotype D predominates
HBsAg-positive egyptian blood donors and is mainly associated with a negative HBeAg serostatus.
Intervirology 2013, 56, 278–283. [CrossRef]
44. Hussein, E. Blood donor recruitment strategies and their impact on blood safety in Egypt. Transfus. Apher.
Sci. 2014, 50, 63–67. [CrossRef]
45. Schweitzer, A.; Horn, J.; Mikolajczyk, R.T.; Krause, G.; Ott, J.J. Estimations of worldwide prevalence of
chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet
2015, 386, 1546–1555. [CrossRef]
46. Abdalla, M.; Hamad, T. Hepatitis B virus Seroprevalence among children with cancer in Sudan. Pediatr.
Blood Cancer 2016, 63, 124–126. [CrossRef]
47. Baha, W.; Foullous, A.; Dersi, N.; They-they, T.P.; Nourichafi, N.; Oukkache, B.; Lazar, F.; Benjelloun, S.;
Ennaji, M.M.; Elmalki, A. Prevalence and risk factors of hepatitis B and C virus infections among the general
population and blood donors in Morocco. BMC Public Health 2013, 13, 50. [CrossRef]
48. Elzouki, A.-N.; Smeo, M.-N.; Sammud, M.; Elahmer, O.; Daw, M.; Furarah, A.; Abudher, A.; Mohamed, M.
Prevalence of hepatitis B and C virus infections and their related risk factors in Libya: A national
seroepidemiological survey. East. Mediterr. Health J. 2013, 19, 589–599. [CrossRef]
49. El-Magrahe, H.; Furarah, A.R.; El-Figih, K.; El-Urshfany, S.; Ghenghesh, K.S. Maternal and neonatal
seroprevalence of Hepatitis B surface antigen (HBsAg) in Tripoli, Libya. J. Infect. Dev. Ctries. 2010, 4, 168–170.
50. Qirbi, N.; Hall, A. Epidemiology of hepatitis B virus infection in the Middle East. East. Mediterr. Health J.
2001, 7, 1034–1045.
51. Alavian, S.M.; Haghbin, H. Relative importance of hepatitis B and C viruses in hepatocellular carcinoma in
EMRO countries and the middle east: A systematic review. Hepat. Mon. 2016, 16, e35106. [CrossRef]
52. Rasul, K.I.; Al-Azawi, S.H.; Chandra, P.; Abou-Alfa, G.K.; Knuth, A. Status of hepatocellular carcinoma in
Gulf region. Chin. Clin. Oncol. 2013, 2, 42. [CrossRef]
53. Gupta, N.; Goyal, M.; Wu, C.H.; Wu, G.Y. The Molecular and Structural Basis of HBV-resistance to Nucleos
(t) ide Analogs. J. Clin. Transl. Hepatol. 2014, 2, 202–211.
54. Buti, M.; Rodriguez-Frias, F.; Jardi, R.; Esteban, R. Hepatitis B virus genome variability and disease
progression: The impact of pre-core mutants and HBV genotypes. J. Clin. Virol. 2005, 34, S79–S82. [CrossRef]
55. Peck, K.M.; Lauring, A.S. Complexities of viral mutation rates. J. Virol. 2018, 92, e01031-17. [CrossRef]
56. Sunbul, M. Hepatitis B virus genotypes: Global distribution and clinical importance. World J.
Gastroenterol. WJG 2014, 20, 5427. [CrossRef]
57. Kramvis, A.; Kew, M. Relationship of genotypes of hepatitis B virus to mutations, disease progression and
response to antiviral therapy. J. Viral Hepat. 2005, 12, 456–464. [CrossRef]
Pathogens 2019, 8, 63 17 of 22
58. Sozzi, V.; Shen, F.; Chen, J.; Colledge, D.; Jackson, K.; Locarnini, S.; Yuan, Z.; Revill, P.A. In vitro studies
identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV
and less severe liver disease. Virology 2018, 519, 190–196. [CrossRef]
59. Abdo, A.A.; Al-Jarallah, B.M.; Sanai, F.M.; Hersi, A.S.; Al-Swat, K.; Azzam, N.A.; Al-Dukhayil, M.;
Al-Maarik, A.; Al-Faleh, F.Z. Hepatitis B genotypes: Relation to clinical outcome in patients with chronic
hepatitis B in Saudi Arabia. World J. Gastroenterol. WJG 2006, 12, 7019. [CrossRef]
60. El-Mowafy, M.; Elgaml, A.; El-Mesery, M.; Elegezy, M. Molecular analysis of Hepatitis B virus sub-genotypes
and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura.
J. Med. Virol. 2017, 89, 1559–1566. [CrossRef]
61. Said, Z.N.A. An overview of occult hepatitis B virus infection. World J. Gastroenterol. WJG 2011, 17, 1927.
[CrossRef]
62. Jamjoom, G.A.; El-Daly, M.M.; Azhar, E.I.; Fallatah, H.I.; Akbar, H.O.; Babatin, M.; Alghamdi, A.S.; Dgdgi, M.I.;
Hamid, M.A.; Qari, Y.A.; et al. Prevalence and molecular characterization of hepatitis D virus in Saudi
Arabia: A single-center study. Saudi. J. Gastroenterol. 2017, 23, 176.
63. Elbahrawy, A.; Alaboudy, A.; El Moghazy, W.; Elwassief, A.; Alashker, A.; Abdallah, A.M. Occult hepatitis B
virus infection in Egypt. World J. Hepatol. 2015, 7, 1671–1678. [CrossRef]
64. Nodeh, M.M.; Mosavat, A.; Valizadeh, N.; Zadeh, A.M.; Boskabadi, A.; Mashkani, B.; Sima, H.; Rafatpanah, H.
Genotype characteristic and phylogenetic analysis of hepatitis B virus in northeast-Iran. Infect. Genet. Evol.
2018, 59, 148–154. [CrossRef]
65. Al Baqlani, S.A.; Sy, B.T.; Ratsch, B.A.; Al Naamani, K.; Al Awaidy, S.; Busaidy, S.A.; Pauli, G.; Bock, C.T.
Molecular epidemiology and genotyping of hepatitis B virus of HBsAg-positive patients in Oman. PLoS ONE
2014, 9, e97759. [CrossRef]
66. Abdelnabi, Z.; Saleh, N.; Baraghithi, S.; Glebe, D.; Azzeh, M. Subgenotypes and mutations in the s and
polymerase genes of hepatitis B virus carriers in the West Bank, palestine. PLoS ONE 2014, 9, e113821.
[CrossRef]
67. Elmaghloub, R.; Elbahrawy, A.; Didamony, G.E.; Elwassief, A.; Saied Mohammad, A.-G.; Alashker, A.;
Zedan, H.; Abdallah, A.M.; Hemidah, M.H.; Elmestikawy, A.; et al. Hepatitis B Virus Genotype E Infection
among Egyptian Health Care Workers. J. Transl. Intern. Med. 2017, 5, 100–105. [CrossRef] [PubMed]
68. Lucifora, J.; Protzer, U. Attacking hepatitis B virus cccDNA–The holy grail to hepatitis B cure. J. Hepatol.
2016, 64, S41–S48. [CrossRef]
69. Guerrero, R.B.; Roberts, L.R. The role of hepatitis B virus integrations in the pathogenesis of human
hepatocellular carcinoma. J. Hepatol. 2005, 42, 760–777. [CrossRef]
70. McMahon, B.J.; Alward, W.L.; Hall, D.B.; Heyward, W.L.; Bender, T.R.; Francis, D.P.; Maynard, J.E. Acute
hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development
of the carrier state. J. Infect. Dis. 1985, 151, 599–603. [CrossRef]
71. Coursaget, P.; Yvonnet, B.; Chotard, J.; Vincelot, P.; Sarr, M.; Diouf, C.; Chiron, J.; Diop-Mar, I. Age-and
sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal).
J. Med. Virol. 1987, 22, 1–5. [CrossRef]
72. Sghaier, I.; Zidi, S.; Mouelhi, L.; Ghazoueni, E.; Brochot, E.; Almawi, W.Y.; Loueslati, B.Y. TLR3 and TLR4 SNP
variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection. Br. J. Biomed. Sci.
2019, 76, 35–41. [CrossRef] [PubMed]
73. Chihab, H.; Zaidane, I.; Elhabazi, A.; Jadid, F.-Z.; El Fihri, R.; Elmessaoudi-Idrissi, M.; Chair, M.; Badre, W.;
Tahiri, M.; Pineau, P. Toll-like receptor 9 polymorphisms and Hepatitis B virus clearance in Moroccan chronic
carriers. Gene 2019, 687, 212–218. [CrossRef] [PubMed]
74. Talaat, R.M.; Abdelkhalek, M.S.; El-Maadawy, E.A.; Abdel-Mageed, W.S.; El-Shenawy, S.Z.; Osman, M.A.
Association of TNF-Alpha gene polymorphisms and susceptibility to hepatitis B virus infection in Egyptians.
Hum. Immunol. 2017, 78, 739–746. [CrossRef]
75. Talaat, R.M.; Dondeti, M.F.; El-Shenawy, S.Z.; Khamiss, O.A. Transforming growth factor-β1 gene
polymorphism (T29C) in Egyptian patients with Hepatitis B virus infection: A preliminary study.
Hepat. Res. Treat. 2013, 2013, 293274. [CrossRef]
76. Sghaier, I.; Zidi, S.; Mouelhi, L.; Dabbech, R.; Ghazouani, E.; Brochot, E.; Stayoussef, M.; Yacoubi-Loueslati, B.
The relationship between TNF alpha gene polymorphisms (−238/−308), TNF RII VNTR (p75) and outcomes
of hepatitis B virus infection in Tunisian population. Gene 2015, 568, 140–145. [CrossRef]
Pathogens 2019, 8, 63 18 of 22
77. Chihab, H.; Jadid, F.Z.; Foka, P.; Zaidane, I.; El Fihry, R.; Georgopoulou, U.; Marchio, A.; Elhabazi, A.;
Chair, M.; Pineau, P. Programmed cell death-1 3′-untranslated region polymorphism is associated with
spontaneous clearance of hepatitis B virus infection. J. Med. Virol. 2018, 90, 1730–1738. [CrossRef]
78. Al-Qahtani, A.A.; Al-Anazi, M.R.; Abdo, A.A.; Sanai, F.M.; Al-Hamoudi, W.; Alswat, K.A.; Al-Ashgar, H.I.;
Khalaf, N.Z.; Eldali, A.M.; Viswan, N.A. Association between HLA variations and chronic hepatitis B virus
infection in Saudi Arabian patients. PLoS ONE 2014, 9, e80445. [CrossRef]
79. Al-Qahtani, A.; Khalak, H.G.; Alkuraya, F.S.; Al-hamoudy, W.; Alswat, K.; Al Balwi, M.A.; Al AbdulKareem, I.;
Sanai, F.M.; Abdo, A.A. Genome-wide association study of chronic hepatitis B virus infection reveals a novel
candidate risk allele on 11q22. 3. J. Med. Genet. 2013, 50, 725–732. [CrossRef] [PubMed]
80. Al-Qahtani, A.A.; Al-Anazi, M.R.; Nazir, N.; Wani, K.; Abdo, A.A.; Sanai, F.M.; Khan, M.Q.; Al-Ashgar, H.I.;
Albenmousa, A.; Al-hamoudi, W.K. Association of single nucleotide polymorphisms in micro RNA s with
susceptibility to hepatitis B virus infection and HBV-related liver complications: A study in a Saudi Arabian
population. J. Viral Hepat. 2017, 24, 1132–1142. [CrossRef] [PubMed]
81. Akcay, I.M.; Katrinli, S.; Ozdil, K.; Doganay, G.D.; Doganay, L. Host genetic factors affecting hepatitis B
infection outcomes: Insights from genome-wide association studies. World J. Gastroenterol. 2018, 24, 3347.
[CrossRef] [PubMed]
82. Tong, S.; Li, J.; Wands, J.R.; Wen, Y.-M. Hepatitis B virus genetic variants: Biological properties and clinical
implications. Emerg. Microbes Infect. 2013, 2, e10. [CrossRef] [PubMed]
83. Chen, M.T.; Billaud, J.-N.; Sällberg, M.; Guidotti, L.G.; Chisari, F.V.; Jones, J.; Hughes, J.; Milich, D.R.
A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen.
Proc. Natl. Acad. Sci. USA 2004, 101, 14913–14918. [CrossRef] [PubMed]
84. Tong, S.; Li, J.; Vitvitski, L.; Trépo, C. Active hepatitis B virus replication in the presence of anti-HBe is
associated with viral variants containing an inactive pre-C region. Virology 1990, 176, 596–603. [CrossRef]
85. Cote, P.J.; Korba, B.E.; Miller, R.H.; Jacob, J.R.; Baldwin, B.H.; Hornbuckle, W.E.; Purcell, R.H.; Tennant, B.C.;
Gerin, J.L. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck
hepatitis virus infection. Hepatology 2000, 31, 190–200. [CrossRef]
86. Yotsumoto, S.; Kojima, M.; Shoji, I.; Yamamoto, K.; Okamoto, H.; Mishiro, S. Fulminant hepatitis related to
transmission of hepatitis B variants with precore mutations between spouses. Hepatology 1992, 16, 31–35.
[CrossRef] [PubMed]
87. Ayari, R.; Lakhoua-Gorgi, Y.; Bouslama, L.; Safar, I.; Kchouk, F.H.; Aouadi, H.; Jendoubi-Ayed, S.; Najjar, T.;
Ayed, K.; Abdallah, T.B. Investigation of DNA sequence in the Basal core promoter, precore, and core
regions of hepatitis B virus from Tunisia shows a shift in genotype prevalence. Hepat. Mon. 2012, 12, e6191.
[CrossRef] [PubMed]
88. Martinot-Peignoux, M.; Lapalus, M.; Laouénan, C.; Lada, O.; Netto-Cardoso, A.C.F.; Boyer, N.; Ripault, M.P.;
Carvalho-Filho, R.; Asselah, T.; Marcellin, P. Prediction of disease reactivation in asymptomatic hepatitis B e
antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
J. Clin. Virol. 2013, 58, 401–407. [CrossRef] [PubMed]
89. Ayed, K.; Gorgi, Y.; Ayed-Jendoubi, S.; Aouadi, H.; Sfar, I.; Najjar, T.; Abdallah, T.B. Hepatitis B virus
genotypes and precore/core-promoter mutations in Tunisian patients with chronic hepatitis B virus infection.
J. Infect. 2007, 54, 291–297. [CrossRef]
90. Alfaresi, M.; Elkoush, A.; Alshehhi, H.; Alzaabi, A.; Islam, A. Hepatitis B virus genotypes and precore and
core mutants in UAE patients. Virol. J. 2010, 7, 160. [CrossRef]
91. Al-Qahtani, A.A.; Al-Anazi, M.R.; Nazir, N.; Abdo, A.A.; Sanai, F.M.; Al-Hamoudi, W.K.; Alswat, K.A.;
Al-Ashgar, H.I.; Khan, M.Q.; Albenmousa, A. The correlation between hepatitis B virus precore/core mutations
and the progression of severe liver disease. Front. Cell. Infect. Microbiol. 2018, 8, 355. [CrossRef]
92. Okamoto, H.; Tsuda, F.; Akahane, Y.; Sugai, Y.; Yoshiba, M.; Moriyama, K.; Tanaka, T.; Miyakawa, Y.;
Mayumi, M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in
carriers with antibody to e antigen. J. Virol. 1994, 68, 8102–8110.
93. Tsai, A.; Kawai, S.; Kwei, K.; Gewaily, D.; Hutter, A.; Tong, D.R.; Li, J.; Wands, J.R.; Tong, S. Chimeric
constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations
and reveal multiple effects of core gene mutations. Virology 2009, 387, 364–372. [CrossRef]
Pathogens 2019, 8, 63 19 of 22
94. Grabarczyk, P.; Garmiri, P.; Liszewski, G.; Doucet, D.; Sulkowska, E.; Brojer, E.; Allain, J.P.; Polish Blood
Transfusion Centres Viral Study Group. Molecular and serological characterization of hepatitis B virus
genotype A and D infected blood donors in Poland. J. Viral Hepat. 2010, 17, 444–452. [CrossRef]
95. Liang, T.J. Hepatitis B: The virus and disease. Hepatology 2009, 49, S13–S21. [CrossRef]
96. Churin, Y.; Roderfeld, M.; Roeb, E. Hepatitis B virus large surface protein: Function and fame. Hepatobiliary
Surg. Nutr. 2015, 4, 1–10.
97. Boltjes, A.; Groothuismink, Z.M.; van Oord, G.W.; Janssen, H.L.; Woltman, A.M.; Boonstra, A. Monocytes
from chronic HBV patients react in vitro to HBsAg and TLR by producing cytokines irrespective of stage of
disease. PLoS ONE 2014, 9, e97006. [CrossRef] [PubMed]
98. Wu, J.; Meng, Z.; Jiang, M.; Pei, R.; Trippler, M.; Broering, R.; Bucchi, A.; Sowa, J.P.; Dittmer, U.; Yang, D.
Hepatitis B virus suppresses toll-like receptor–mediated innate immune responses in murine parenchymal
and nonparenchymal liver cells. Hepatology 2009, 49, 1132–1140. [CrossRef] [PubMed]
99. Gehring, A.J.; Haniffa, M.; Kennedy, P.T.; Ho, Z.Z.; Boni, C.; Shin, A.; Banu, N.; Chia, A.; Lim, S.G.; Ferrari, C.
Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J. Clin. Investig. 2013,
123, 3766–3776. [CrossRef] [PubMed]
100. Chen, C.-H.; Changchien, C.-S.; Lee, C.-M.; Hung, C.-H.; Hu, T.-H.; Wang, J.-H.; Wang, J.-C.; Lu, S.-N.
Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk
of hepatocellular carcinoma: A case-control study. J. Infect. Dis. 2008, 198, 1634–1642. [CrossRef] [PubMed]
101. Hsieh, Y.-H.; Su, I.-J.; Wang, H.-C.; Tsai, J.-H.; Huang, Y.-J.; Chang, W.-W.; Lai, M.-D.; Lei, H.-Y.; Huang, W.
Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor
p27Kip1 through c-Jun activation domain-binding protein 1. Mol. Cancer Res. 2007, 5, 1063–1072. [CrossRef]
[PubMed]
102. Chen, B.F.; Liu, C.J.; Jow, G.M.; Chen, P.J.; Kao, J.H.; Chen, D.S. High prevalence and mapping of pre-S
deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006, 130, 1153–1168.
[CrossRef]
103. Elkady, A.; Iijima, S.; Aboulfotuh, S.; Ali, E.M.; Sayed, D.; Abdel-Aziz, N.M.; Ali, A.M.; Murakami, S.;
Isogawa, M.; Tanaka, Y. Characteristics of escape mutations from occult hepatitis B virus infected patients
with hematological malignancies in South Egypt. World J. Hepatol. 2017, 9, 477. [CrossRef]
104. Zeid, W.M.A.; Ramadan, D.I.; Shemis, M.A. Prevalence of mutations within major hydrophilic region of
hepatitis B virus and their correlation with genotypes among chronically infected patients in Egypt. Arab J.
Gastroenterol. 2016, 17, 34–40. [CrossRef] [PubMed]
105. Al-Qudari, A.Y.; Amer, H.M.; Abdo, A.A.; Hussain, Z.; Al-Hamoudi, W.; Alswat, K.; Almajhdi, F.N. Surface
gene variants of hepatitis B Virus in Saudi Patients. Saudi J. Gastroenterol. Off. J. Saudi Gastroenterol. Assoc.
2016, 22, 133–138.
106. Chaouch, H.; Taffon, S.; Villano, U.; Equestre, M.; Bruni, R.; Belhadj, M.; Hannachi, N.; Aouni, M.; Letaief, A.;
Ciccaglione, A.R. Naturally occurring surface antigen variants of hepatitis B virus in Tunisian patients.
Intervirology 2016, 59, 36–47. [CrossRef] [PubMed]
107. Hwang, G.-Y.; Lin, C.-Y.; Huang, L.-M.; Wang, Y.-H.; Wang, J.-C.; Hsu, C.-T.; Yang, S.-S.; Wu, C.-C. Detection
of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular
carcinoma. J. Clin. Microbiol. 2003, 41, 5598–5603. [CrossRef]
108. Yang, B.; Bouchard, M.J. The hepatitis B virus X protein elevates cytosolic calcium signals by modulating
mitochondrial calcium uptake. J. Virol. 2012, 86, 313–327. [CrossRef]
109. Pan, J.; Lian, Z.; Wallet, S.; Feitelson, M.A. The hepatitis B x antigen effector, URG7, blocks tumour necrosis
factor α-mediated apoptosis by activation of phosphoinositol 3-kinase and β-catenin. J. Gen. Virol. 2007, 88,
3275–3285. [CrossRef] [PubMed]
110. Bouchard, M.J.; Puro, R.J.; Wang, L.; Schneider, R.J. Activation and inhibition of cellular calcium and tyrosine
kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication.
J. Virol. 2003, 77, 7713–7719. [CrossRef] [PubMed]
111. Ma, N.-F.; Lau, S.H.; Hu, L.; Xie, D.; Wu, J.; Yang, J.; Wang, Y.; Wu, M.-C.; Fung, J.; Bai, X. COOH-terminal
truncated HBV X protein plays key role in hepatocarcinogenesis. Clin. Cancer Res. 2008, 14, 5061–5068.
[CrossRef]
Pathogens 2019, 8, 63 20 of 22
112. Al-Qahtani, A.A.; Al-Anazi, M.R.; Nazir, N.; Ghai, R.; Abdo, A.A.; Sanai, F.M.; Al-Hamoudi, W.K.;
Alswat, K.A.; Al-Ashgar, H.I.; Khan, M.Q. Hepatitis B virus (HBV) X gene mutations and their association
with liver disease progression in HBV-infected patients. Oncotarget 2017, 8, 105115. [CrossRef] [PubMed]
113. Al-Anazi, M.R.; Nazir, N.; Colak, D.; Al-Ahdal, M.N.; Al-Qahtani, A.A. Deletion and Functional Analysis of
Hepatitis B Virus X Protein: Evidence for an Effect on Cell Cycle Regulators. Cell. Physiol. Biochem. 2018, 49,
1987–1998. [CrossRef]
114. El-Zayadi, A.R.; Abe, K.; Selim, O.; Naito, H.; Hess, G.; Ahdy, A. Prevalence of GBV-C/hepatitis G virus
viraemia among blood donors, health care personnel, chronic non-B non-C hepatitis, chronic hepatitis C and
hemodialysis patients in Egypt. J. Virol. Methods 1999, 80, 53–58. [CrossRef]
115. Hussain, T.; Manzoor, S.; Waheed, Y.; Tariq, H.; Hanif, K. Phylogenetic analysis of Torque Teno Virus genome
from Pakistani isolate and incidence of co-infection among HBV/HCV infected patients. Virol. J. 2012, 9, 320.
[CrossRef]
116. McArdle, A.J.; Turkova, A.; Cunnington, A.J. When do coinfections matter? Curr. Opin. Infect. Dis. 2018.
[CrossRef] [PubMed]
117. Rodriguez-Inigo, E.; Bartolome, J.; Ortiz-Movilla, N.; Platero, C.; Lopez-Alcorocho, J.M.; Pardo, M.; Castillo, I.;
Carreno, V. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver
of patients with chronic HCV and occult HBV infection. J. Virol. 2005, 79, 15578–15581. [CrossRef] [PubMed]
118. Torbenson, M.; Thomas, D.L. Occult hepatitis B. Lancet Infect. Dis. 2002, 2, 479–486. [CrossRef]
119. Potthoff, A.; Wedemeyer, H.; Boecher, W.O.; Berg, T.; Zeuzem, S.; Arnold, J.; Spengler, U.; Gruengreiff, K.;
Kaeser, T.; Schuchmann, M.; et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to
investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.
J. Hepatol. 2008, 49, 688–694. [CrossRef]
120. Fukuda, R.; Ishimura, N.; Niigaki, M.; Hamamoto, S.; Satoh, S.; Tanaka, S.; Kushiyama, Y.; Uchida, Y.;
Ihihara, S.; Akagi, S.; et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C
virus-associated chronic liver disease: Clinical and virological significance. J. Med. Virol. 1999, 58, 201–207.
[CrossRef]
121. Fong, T.L.; Di Bisceglie, A.M.; Waggoner, J.G.; Banks, S.M.; Hoofnagle, J.H. The significance of antibody to
hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991, 14, 64–67. [CrossRef]
122. Chiaramonte, M.; Stroffolini, T.; Vian, A.; Stazi, M.A.; Floreani, A.; Lorenzoni, U.; Lobello, S.; Farinati, F.;
Naccarato, R. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Cancer 1999, 85, 2132–2137. [CrossRef]
123. Donato, F.; Boffetta, P.; Puoti, M. A meta-analysis of epidemiological studies on the combined effect of
hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer 1998, 75, 347–354.
[CrossRef]
124. Thio, C.L. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49, S138–S145.
[CrossRef] [PubMed]
125. El-Gilany, A.H.; El-Fedawy, S. Bloodborne infections among student voluntary blood donors in Mansoura
University, Egypt. East. Mediterr. Health J. 2006, 12, 742–748.
126. Al-Mughales, J.A. Co-infection assessment in HBV, HCV, and HIV patients in Western Saudi Arabia. J. Med.
Virol. 2016, 88, 1545–1551. [CrossRef]
127. Afsar, I.; Gungor, S.; Sener, A.G.; Yurtsever, S.G. The prevalence of HBV, HCV and HIV infections among
blood donors in Izmir, Turkey. Indian J. Med. Microbiol. 2008, 26, 288–289. [CrossRef]
128. Thio, C.L.; Seaberg, E.C.; Skolasky, R., Jr.; Phair, J.; Visscher, B.; Munoz, A.; Thomas, D.L.; Multicenter, A.C.S.
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet
2002, 360, 1921–1926. [CrossRef]
129. Hawkins, C.; Christian, B.; Fabian, E.; Macha, I.; Gawile, C.; Mpangala, S.; Ulenga, N.; Thio, C.L.;
Ammerman, L.R.; Mugusi, F.; et al. Brief Report: HIV/HBV Coinfection is a Significant Risk Factor for Liver
Fibrosis in Tanzanian HIV-Infected Adults. J. Acquir. Immune Defic. Syndr. 2017, 76, 298–302. [CrossRef]
[PubMed]
130. Kourtis, A.P.; Bulterys, M.; Hu, D.J.; Jamieson, D.J. HIV-HBV coinfection—A global challenge. N. Engl. J. Med.
2012, 366, 1749–1752. [CrossRef] [PubMed]
Pathogens 2019, 8, 63 21 of 22
131. Kalkan, A.; Ozdarendeli, A.; Bulut, Y.; Saral, Y.; Ozden, M.; Kelestimur, N.; Toraman, Z.A. Prevalence and
genotypic distribution of hepatitis GB-C/HG and TT viruses in blood donors, mentally retarded children and
four groups of patients in eastern Anatolia, Turkey. Jpn. J. Infect. Dis. 2005, 58, 222–227.
132. AbuOdeh, R.; Al-Mawlawi, N.; Al-Qahtani, A.A.; Bohol, M.F.; Al-Ahdal, M.N.; Hasan, H.A.; AbuOdeh, L.;
Nasrallah, G.K. Detection and genotyping of torque teno virus (TTV) in healthy blood donors and patients
infected with HBV or HCV in Qatar. J. Med. Virol. 2015, 87, 1184–1191. [CrossRef]
133. Al-Mozaini, M.A.; Al-Ahdal, M.N.; Kessie, G.; Dela Cruz, D.M.; Rezeig, M.A.; Al-Shammary, F.J. Molecular
epidemiology and genotyping of TT virus isolated from Saudi blood donors and hepatitis patients.
Ann. Saudi Med. 2006, 26, 444–449. [CrossRef] [PubMed]
134. Hafez, M.M.; Shaarawy, S.M.; Hassan, A.A.; Salim, R.F.; Abd El Salam, F.M.; Ali, A.E. Prevalence of
transfusion transmitted virus (TTV) genotypes among HCC patients in Qaluobia governorate. Virol. J. 2007,
4, 135. [CrossRef]
135. Kasirga, E.; Sanlidag, T.; Akcali, S.; Keskin, S.; Aktas, E.; Karakoc, Z.; Helvaci, M.; Sozen, G.; Kuzu, M.
Clinical significance of TT virus infection in children with chronic hepatitis B. Pediatr. Int. 2005, 47, 300–304.
[CrossRef]
136. AbuOdeh, R.O.; Al-Absi, E.; Ali, N.H.; Khalili, M.; Al-Mawlawi, N.; Hadwan, T.A.; Althani, A.A.;
Nasrallah, G.K. Detection and phylogenetic analysis of human pegivirus (GBV-C) among blood donors and
patients infected with hepatitis B virus (HBV) in Qatar. J. Med. Virol. 2015, 87, 2074–2081. [CrossRef]
137. Zaki Mel, S.; Salama, O.S.; Mansour, F.A.; Hossein, S. Hepatitis E virus coinfection with hepatotropic viruses
in Egyptian children. J. Microbiol. Immunol. Infect. 2008, 41, 254–258. [PubMed]
138. Taremi, M.; Khoshbaten, M.; Gachkar, L.; EhsaniArdakani, M.; Zali, M. Hepatitis E virus infection in
hemodialysis patients: A seroepidemiological survey in Iran. BMC Infect. Dis. 2005, 5, 36. [CrossRef]
[PubMed]
139. World Health Organization. Hepatitis E. Available online: http://www.who.int/news-room/fact-sheets/detail/
hepatitis-e (accessed on 1 January 2019).
140. Al-Sadeq, D.W.; Majdalawieh, A.F.; Mesleh, A.G.; Abdalla, O.M.; Nasrallah, G.K. Laboratory challenges in
the diagnosis of hepatitis E virus. J. Med. Microbiol. 2018, 67, 466–480. [CrossRef]
141. Kheradpezhouh, M.; Taremi, M.; Gachkar, L.; Aghabozorgi, S.; Khoshbaten, M. Presence and significance
of transfusion-transmitted virus infection in Iranian patients on maintenance hemodialysis. J. Microbiol.
Immunol. Infect. 2007, 40, 106–111.
142. Hoan, N.X.; Tong, H.V.; Hecht, N.; Sy, B.T.; Marcinek, P.; Meyer, C.G.; Song, L.H.; Toan, N.L.; Kurreck, J.;
Kremsner, P.G.; et al. Hepatitis E Virus Superinfection and Clinical Progression in Hepatitis B Patients.
EBioMedicine 2015, 2, 2080–2086. [CrossRef] [PubMed]
143. Alhetheel, A.; El-Hazmi, M.M. Hepatitis G virus in Saudi blood donors and chronic hepatitis B and C patients.
J. Infect. Dev. Ctries. 2014, 8, 110–115. [CrossRef] [PubMed]
144. Yazdani, L.; Ravanshad, M.; Khanlari, Z.; Dawood Mousavi Nasab, S.; Ali Ahmadi, N.; Imanzad, M.
Prevalence of GBV-C among Iranian HBV positive patients using PCR-RFLP technique. Gastroenterol. Hepatol.
Bed Bench 2013, 6, S70–S76. [PubMed]
145. Fiordalisi, G.; Zanella, I.; Mantero, G.; Bettinardi, A.; Stellini, R.; Paraninfo, G.; Cadeo, G.; Primi, D. High
prevalence of GB virus C infection in a group of Italian patients with hepatitis of unknown etiology. J. Infect.
Dis. 1996, 174, 181–183. [CrossRef]
146. Yoshiba, M.; Okamoto, H.; Mishiro, S. Detection of the GBV-C hepatitis virus genome in serum from patients
with fulminant hepatitis of unknown aetiology. Lancet 1995, 346, 1131–1132. [CrossRef]
147. Laskus, T.; Radkowski, M.; Wang, L.F.; Vargas, H.; Rakela, J. Lack of evidence for hepatitis G virus replication
in the livers of patients coinfected with hepatitis C and G viruses. J. Virol. 1997, 71, 7804–7806.
148. Alter, H.J. G-pers creepers, where’d you get those papers? A reassessment of the literature on the hepatitis G
virus. Transfusion 1997, 37, 569–572. [CrossRef] [PubMed]
149. Yang, J.F.; Dai, C.Y.; Chuang, W.L.; Lin, W.Y.; Lin, Z.Y.; Chen, S.C.; Hsieh, M.Y.; Wang, L.Y.; Tsai, J.F.;
Chang, W.Y.; et al. Prevalence and clinical significance of HGV/GBV-C infection in patients with chronic
hepatitis B or C. Jpn. J. Infect. Dis. 2006, 59, 25–30. [PubMed]
150. Kao, J.H.; Chen, P.J.; Lai, M.Y.; Chen, W.; Chen, D.S. Effects of GB virus-C/hepatitis G virus on hepatitis B and
C viremia in multiple hepatitis virus infections. Arch. Virol. 1998, 143, 797–802. [CrossRef] [PubMed]
Pathogens 2019, 8, 63 22 of 22
151. Köse, S¸.; Dal, T. Laboratory Diagnosis of HBV. In Viral Hepatitis: Chronic Hepatitis B; Springer:
Berlin/Heidelberg, Germany, 2018; pp. 51–64.
152. Mühlbacher, A.; Weber, B.; Bürgisser, P.; Eiras, A.; Cabrera, J.; Louisirirotchanakul, S.; Tiller, F.-W.; Kim, H.-S.;
Helden, J.V.; Bossi, V. Multicenter study of a new fully automated HBsAg screening assay with enhanced
sensitivity for the detection of HBV mutants. Med. Microbiol. Immunol. 2008, 197, 55–64. [CrossRef]
153. Alawi, F.B.; Robertson, P.W.; LePage, A.K.; Jayamaha, J.; Baleriola, C.; Rawlinson, W.D. The reliability of HBV
core antibody in serological screening for hepatitis B virus. Pathology 2013, 45, 501–505. [CrossRef] [PubMed]
154. Maity, S.; Nandi, S.; Biswas, S.; Sadhukhan, S.K.; Saha, M.K. Performance and diagnostic usefulness of
commercially available enzyme linked immunosorbent assay and rapid kits for detection of HIV, HBV and
HCV in India. Virol. J. 2012, 9, 290. [CrossRef] [PubMed]
155. Zacher, B.; Moriconi, F.; Bowden, S.; Hammond, R.; Louisirirotchanakul, S.; Phisalprapa, P.; Tanwandee, T.;
Wursthorn, K.; Brunetto, M.R.; Wedemeyer, H. Multicenter evaluation of the Elecsys HBsAg II quant assay.
Clin. Vaccine Immunol. 2011, 18, 1943–1950. [CrossRef]
156. Deguchi, M.; Yamashita, N.; Kagita, M.; Asari, S.; Iwatani, Y.; Tsuchida, T.; Iinuma, K.; Mushahwar, I.K.
Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay.
J. Virol. Methods 2004, 115, 217–222. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
